Stryker (SYK) Q3 2026 Earnings
Adjusted EPS excludes a $293 million goodwill impairment ($0.76 per share), $175 million amortization of purchased intangibles ($0.37), $153 million structural optimization and other special charges incl. $77 million Spinal Implants sale related ($0.20), $32 million regulatory and legal matters ($0.07), and $50 million tax matters ($0.11). GAAP diluted EPS was $1.96.
How Did SYK Stock React to Q3 2026 Earnings?
Did SYK Beat Earnings? Q3 2026 Results
No. Stryker reported Q3 2026 earnings of $3.52 a share on Oct 29, 2026, missing the $3.55 consensus estimate by 0.8%. Revenue was $6.5B against a $6.6B estimate.
Stryker Corp delivered a quarter of solid underlying growth clouded by a painful non-cash charge, as the medical technology company missed on both the top and bottom lines for Q3 2026, snapping a six-consecutive-quarter streak of beating consensus EPS estimates. Adjusted EPS came in at $3.52, falling just short of the $3.55 analyst consensus, while revenue of $6.52 billion trailed expectations of $6.62 billion despite rising 7.6% from a year ago. The headline GAAP result was far weaker, with net earnings falling 12.3% to $753.00 million, or $1.96 per diluted share, dragged down primarily by a $293.00 million goodwill impairment that carried no tax benefit and reduced diluted EPS by $0.76. Bright spots included MedSurg and Neurotechnology's 9.1% organic growth, led by Endoscopy's 13.9% reported gain, and a $1.00 billion share repurchase in the quarter with the Board adding another $3.00 billion to the buyback program in October. CEO Kevin Lobo acknowledged the shortfall but pointed to strong fundamentals, and the company updated its full-year 2026 guidance to 6.5% to 7.0% organic sales growth and adjusted EPS of $14.80 to $14.90, with Lobo projecting solid Q4 momentum carrying into 2027.
- Organic net sales growth of 7.7% primarily driven by increased unit volume
- MedSurg and Neurotechnology organic growth of 9.1%, led by Endoscopy (+13.9%) and Medical (+9.7%)
- Ortho Tech sales up 15.8%, with U.S. sales up 18.1%
- U.S. Vascular sales up 13.0%
- Adjusted operating margin expanded 60 bps to 26.2%
- Hips sales declined 1.0% and Knees grew only 1.1%
- $293 million goodwill impairment weighed on GAAP net earnings, which fell 12.3%
“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter.”
Stryker CEO, on the earnings call
What Is Stryker's Outlook?
Stryker updated its full-year 2026 guidance. It now expects organic net sales growth of 6.5% to 7.0% and adjusted net earnings per diluted share of $14.80 to $14.90. The sales guidance includes a modestly positive pricing impact. Foreign exchange is expected to have a slightly favorable impact on both sales and adjusted EPS if rates hold near current levels. The CEO expects a solid Q4 performance and good momentum heading into 2027.
SYK YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $6.5B | $6.1B | +7.6% |
| Gross Profit | $4.2B | $3.9B | +10.3% |
| Operating Income | $1.0B | $1.1B | −8.9% |
| Net Income | $753.0M | $859.0M | −12.3% |
SYK Revenue by Segment
SYK Revenue by Geography
When Does Stryker Report Next?
Figures from SEC filings and company reports. Not investment advice.